nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxylamine—Dry mouth—Leflunomide—systemic scleroderma	0.00199	0.00199	CcSEcCtD
Doxylamine—Vomiting—Pentoxifylline—systemic scleroderma	0.00198	0.00198	CcSEcCtD
Doxylamine—Convulsion—Mycophenolic acid—systemic scleroderma	0.00197	0.00197	CcSEcCtD
Doxylamine—Muscle spasms—Lisinopril—systemic scleroderma	0.00197	0.00197	CcSEcCtD
Doxylamine—Rash—Pentoxifylline—systemic scleroderma	0.00197	0.00197	CcSEcCtD
Doxylamine—Dermatitis—Pentoxifylline—systemic scleroderma	0.00197	0.00197	CcSEcCtD
Doxylamine—Anaphylactic shock—Leflunomide—systemic scleroderma	0.00195	0.00195	CcSEcCtD
Doxylamine—Feeling abnormal—Captopril—systemic scleroderma	0.00195	0.00195	CcSEcCtD
Doxylamine—Anxiety—Mycophenolic acid—systemic scleroderma	0.00193	0.00193	CcSEcCtD
Doxylamine—Asthenia—Mometasone—systemic scleroderma	0.00193	0.00193	CcSEcCtD
Doxylamine—Irritability—Prednisone—systemic scleroderma	0.00193	0.00193	CcSEcCtD
Doxylamine—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.00193	0.00193	CcSEcCtD
Doxylamine—Hypotension—Azathioprine—systemic scleroderma	0.00193	0.00193	CcSEcCtD
Doxylamine—Polyuria—Methotrexate—systemic scleroderma	0.00193	0.00193	CcSEcCtD
Doxylamine—Tremor—Lisinopril—systemic scleroderma	0.00192	0.00192	CcSEcCtD
Doxylamine—Mood swings—Prednisone—systemic scleroderma	0.00192	0.00192	CcSEcCtD
Doxylamine—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.00192	0.00192	CcSEcCtD
Doxylamine—Discomfort—Mycophenolic acid—systemic scleroderma	0.00192	0.00192	CcSEcCtD
Doxylamine—Nervous system disorder—Leflunomide—systemic scleroderma	0.00191	0.00191	CcSEcCtD
Doxylamine—Thrombocytopenia—Leflunomide—systemic scleroderma	0.00191	0.00191	CcSEcCtD
Doxylamine—Pruritus—Mometasone—systemic scleroderma	0.00191	0.00191	CcSEcCtD
Doxylamine—Ill-defined disorder—Lisinopril—systemic scleroderma	0.0019	0.0019	CcSEcCtD
Doxylamine—Tachycardia—Leflunomide—systemic scleroderma	0.0019	0.0019	CcSEcCtD
Doxylamine—Dry mouth—Mycophenolic acid—systemic scleroderma	0.0019	0.0019	CcSEcCtD
Doxylamine—Hyperhidrosis—Leflunomide—systemic scleroderma	0.00188	0.00188	CcSEcCtD
Doxylamine—Angioedema—Lisinopril—systemic scleroderma	0.00188	0.00188	CcSEcCtD
Doxylamine—Confusional state—Mycophenolic acid—systemic scleroderma	0.00188	0.00188	CcSEcCtD
Doxylamine—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00186	0.00186	CcSEcCtD
Doxylamine—Anorexia—Leflunomide—systemic scleroderma	0.00186	0.00186	CcSEcCtD
Doxylamine—Nausea—Pentoxifylline—systemic scleroderma	0.00185	0.00185	CcSEcCtD
Doxylamine—Malaise—Lisinopril—systemic scleroderma	0.00185	0.00185	CcSEcCtD
Doxylamine—Vertigo—Lisinopril—systemic scleroderma	0.00184	0.00184	CcSEcCtD
Doxylamine—Diarrhoea—Mometasone—systemic scleroderma	0.00184	0.00184	CcSEcCtD
Doxylamine—Leukopenia—Lisinopril—systemic scleroderma	0.00184	0.00184	CcSEcCtD
Doxylamine—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00182	0.00182	CcSEcCtD
Doxylamine—Hypotension—Leflunomide—systemic scleroderma	0.00182	0.00182	CcSEcCtD
Doxylamine—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.00182	0.00182	CcSEcCtD
Doxylamine—Tachycardia—Mycophenolic acid—systemic scleroderma	0.00181	0.00181	CcSEcCtD
Doxylamine—Palpitations—Lisinopril—systemic scleroderma	0.00181	0.00181	CcSEcCtD
Doxylamine—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.0018	0.0018	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00178	0.00178	CcSEcCtD
Doxylamine—Anorexia—Mycophenolic acid—systemic scleroderma	0.00177	0.00177	CcSEcCtD
Doxylamine—Insomnia—Leflunomide—systemic scleroderma	0.00176	0.00176	CcSEcCtD
Doxylamine—Anxiety—Lisinopril—systemic scleroderma	0.00174	0.00174	CcSEcCtD
Doxylamine—Dyspnoea—Leflunomide—systemic scleroderma	0.00174	0.00174	CcSEcCtD
Doxylamine—Hypotension—Mycophenolic acid—systemic scleroderma	0.00174	0.00174	CcSEcCtD
Doxylamine—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.00173	0.00173	CcSEcCtD
Doxylamine—Discomfort—Lisinopril—systemic scleroderma	0.00173	0.00173	CcSEcCtD
Doxylamine—Pancreatitis—Prednisone—systemic scleroderma	0.00172	0.00172	CcSEcCtD
Doxylamine—Vomiting—Mometasone—systemic scleroderma	0.00171	0.00171	CcSEcCtD
Doxylamine—Dry mouth—Lisinopril—systemic scleroderma	0.00171	0.00171	CcSEcCtD
Doxylamine—Sweating increased—Prednisone—systemic scleroderma	0.0017	0.0017	CcSEcCtD
Doxylamine—Feeling abnormal—Azathioprine—systemic scleroderma	0.0017	0.0017	CcSEcCtD
Doxylamine—Rash—Mometasone—systemic scleroderma	0.0017	0.0017	CcSEcCtD
Doxylamine—Asthenia—Captopril—systemic scleroderma	0.0017	0.0017	CcSEcCtD
Doxylamine—Dermatitis—Mometasone—systemic scleroderma	0.0017	0.0017	CcSEcCtD
Doxylamine—Decreased appetite—Leflunomide—systemic scleroderma	0.00169	0.00169	CcSEcCtD
Doxylamine—Confusional state—Lisinopril—systemic scleroderma	0.00169	0.00169	CcSEcCtD
Doxylamine—Tremor—Mycophenolate mofetil—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Doxylamine—Insomnia—Mycophenolic acid—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Doxylamine—Fatigue—Leflunomide—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Doxylamine—Anaphylactic shock—Lisinopril—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Doxylamine—Pruritus—Captopril—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Doxylamine—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Doxylamine—Constipation—Leflunomide—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Doxylamine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00166	0.00166	CcSEcCtD
Doxylamine—Somnolence—Mycophenolic acid—systemic scleroderma	0.00165	0.00165	CcSEcCtD
Doxylamine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.00165	0.00165	CcSEcCtD
Doxylamine—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Doxylamine—Thrombocytopenia—Lisinopril—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Doxylamine—Tachycardia—Lisinopril—systemic scleroderma	0.00163	0.00163	CcSEcCtD
Doxylamine—Malaise—Mycophenolate mofetil—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Doxylamine—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Doxylamine—Diarrhoea—Captopril—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Doxylamine—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Doxylamine—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Doxylamine—Irritability—Methotrexate—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Doxylamine—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Doxylamine—Feeling abnormal—Leflunomide—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Doxylamine—Fatigue—Mycophenolic acid—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Doxylamine—Mood swings—Methotrexate—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Doxylamine—Nausea—Mometasone—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Doxylamine—Anorexia—Lisinopril—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Doxylamine—Constipation—Mycophenolic acid—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Doxylamine—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Doxylamine—Hypotension—Lisinopril—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Doxylamine—Dizziness—Captopril—systemic scleroderma	0.00156	0.00156	CcSEcCtD
Doxylamine—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.00156	0.00156	CcSEcCtD
Doxylamine—Depression—Prednisone—systemic scleroderma	0.00156	0.00156	CcSEcCtD
Doxylamine—Urticaria—Leflunomide—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Doxylamine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Doxylamine—Breast disorder—Methotrexate—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Doxylamine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Doxylamine—Hypersensitivity—Azathioprine—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Doxylamine—Insomnia—Lisinopril—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Doxylamine—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Doxylamine—Vomiting—Captopril—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Doxylamine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Doxylamine—Dyspnoea—Lisinopril—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Doxylamine—Rash—Captopril—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Doxylamine—Dermatitis—Captopril—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Doxylamine—Somnolence—Lisinopril—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Doxylamine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Doxylamine—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Doxylamine—Decreased appetite—Lisinopril—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Doxylamine—Fatigue—Lisinopril—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Doxylamine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Doxylamine—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Doxylamine—Hypersensitivity—Leflunomide—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Doxylamine—Pancreatitis—Methotrexate—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Doxylamine—Constipation—Lisinopril—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Doxylamine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Doxylamine—Bradycardia—Prednisone—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Doxylamine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.00142	0.00142	CcSEcCtD
Doxylamine—Diarrhoea—Azathioprine—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Doxylamine—Nausea—Captopril—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Doxylamine—Abdominal discomfort—Methotrexate—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Doxylamine—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Doxylamine—Asthenia—Leflunomide—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Doxylamine—Hallucination—Prednisone—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Doxylamine—Pancytopenia—Methotrexate—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Doxylamine—Feeling abnormal—Lisinopril—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Doxylamine—Pruritus—Leflunomide—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Doxylamine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Doxylamine—Dizziness—Azathioprine—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Doxylamine—Asthenia—Mycophenolic acid—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Doxylamine—Diarrhoea—Leflunomide—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Doxylamine—Urticaria—Lisinopril—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Doxylamine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Doxylamine—Pruritus—Mycophenolic acid—systemic scleroderma	0.00132	0.00132	CcSEcCtD
Doxylamine—Vomiting—Azathioprine—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Doxylamine—Eye disorder—Prednisone—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Doxylamine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Doxylamine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Doxylamine—Drowsiness—Methotrexate—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Doxylamine—Rash—Azathioprine—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Doxylamine—Dermatitis—Azathioprine—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Doxylamine—Depression—Methotrexate—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Doxylamine—Flushing—Prednisone—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Doxylamine—Dizziness—Leflunomide—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Doxylamine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.00128	0.00128	CcSEcCtD
Doxylamine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00127	0.00127	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00127	0.00127	CcSEcCtD
Doxylamine—Immune system disorder—Prednisone—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Doxylamine—Constipation—Mycophenolate mofetil—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Doxylamine—Sweating—Methotrexate—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Doxylamine—Vomiting—Leflunomide—systemic scleroderma	0.00124	0.00124	CcSEcCtD
Doxylamine—Hypersensitivity—Lisinopril—systemic scleroderma	0.00123	0.00123	CcSEcCtD
Doxylamine—Dizziness—Mycophenolic acid—systemic scleroderma	0.00123	0.00123	CcSEcCtD
Doxylamine—Rash—Leflunomide—systemic scleroderma	0.00123	0.00123	CcSEcCtD
Doxylamine—Dermatitis—Leflunomide—systemic scleroderma	0.00123	0.00123	CcSEcCtD
Doxylamine—Nausea—Azathioprine—systemic scleroderma	0.00123	0.00123	CcSEcCtD
Doxylamine—Erythema—Prednisone—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Doxylamine—Agranulocytosis—Methotrexate—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Doxylamine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Doxylamine—Asthenia—Lisinopril—systemic scleroderma	0.0012	0.0012	CcSEcCtD
Doxylamine—Pruritus—Lisinopril—systemic scleroderma	0.00119	0.00119	CcSEcCtD
Doxylamine—Vomiting—Mycophenolic acid—systemic scleroderma	0.00118	0.00118	CcSEcCtD
Doxylamine—Rash—Mycophenolic acid—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Doxylamine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Doxylamine—Hepatitis—Methotrexate—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Doxylamine—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Doxylamine—Nausea—Leflunomide—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Doxylamine—Urinary tract disorder—Methotrexate—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Doxylamine—Urethral disorder—Methotrexate—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Doxylamine—Diarrhoea—Lisinopril—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Doxylamine—Ill-defined disorder—Prednisone—systemic scleroderma	0.00113	0.00113	CcSEcCtD
Doxylamine—Agitation—Prednisone—systemic scleroderma	0.00112	0.00112	CcSEcCtD
Doxylamine—Angioedema—Prednisone—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Doxylamine—Dizziness—Lisinopril—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Doxylamine—Erythema multiforme—Methotrexate—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Doxylamine—Nausea—Mycophenolic acid—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Doxylamine—Malaise—Prednisone—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Doxylamine—Vertigo—Prednisone—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Doxylamine—Eye disorder—Methotrexate—systemic scleroderma	0.00109	0.00109	CcSEcCtD
Doxylamine—Cardiac disorder—Methotrexate—systemic scleroderma	0.00109	0.00109	CcSEcCtD
Doxylamine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00108	0.00108	CcSEcCtD
Doxylamine—Vomiting—Lisinopril—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Doxylamine—Immune system disorder—Methotrexate—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Doxylamine—Rash—Lisinopril—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Doxylamine—Convulsion—Prednisone—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Doxylamine—Dermatitis—Lisinopril—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Doxylamine—Mediastinal disorder—Methotrexate—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Doxylamine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Doxylamine—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Doxylamine—Anxiety—Prednisone—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Doxylamine—Discomfort—Prednisone—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Doxylamine—Erythema—Methotrexate—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Doxylamine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.001	0.001	CcSEcCtD
Doxylamine—Nausea—Lisinopril—systemic scleroderma	0.000995	0.000995	CcSEcCtD
Doxylamine—Anaphylactic shock—Prednisone—systemic scleroderma	0.000995	0.000995	CcSEcCtD
Doxylamine—Nervous system disorder—Prednisone—systemic scleroderma	0.000976	0.000976	CcSEcCtD
Doxylamine—Tachycardia—Prednisone—systemic scleroderma	0.000971	0.000971	CcSEcCtD
Doxylamine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00097	0.00097	CcSEcCtD
Doxylamine—Hyperhidrosis—Prednisone—systemic scleroderma	0.000962	0.000962	CcSEcCtD
Doxylamine—Anorexia—Prednisone—systemic scleroderma	0.000948	0.000948	CcSEcCtD
Doxylamine—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000945	0.000945	CcSEcCtD
Doxylamine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000933	0.000933	CcSEcCtD
Doxylamine—Rash—Mycophenolate mofetil—systemic scleroderma	0.000925	0.000925	CcSEcCtD
Doxylamine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000924	0.000924	CcSEcCtD
Doxylamine—Malaise—Methotrexate—systemic scleroderma	0.000919	0.000919	CcSEcCtD
Doxylamine—Vertigo—Methotrexate—systemic scleroderma	0.000915	0.000915	CcSEcCtD
Doxylamine—Leukopenia—Methotrexate—systemic scleroderma	0.000912	0.000912	CcSEcCtD
Doxylamine—Insomnia—Prednisone—systemic scleroderma	0.0009	0.0009	CcSEcCtD
Doxylamine—Convulsion—Methotrexate—systemic scleroderma	0.000883	0.000883	CcSEcCtD
Doxylamine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000872	0.000872	CcSEcCtD
Doxylamine—Decreased appetite—Prednisone—systemic scleroderma	0.000865	0.000865	CcSEcCtD
Doxylamine—Fatigue—Prednisone—systemic scleroderma	0.000858	0.000858	CcSEcCtD
Doxylamine—Discomfort—Methotrexate—systemic scleroderma	0.000857	0.000857	CcSEcCtD
Doxylamine—Constipation—Prednisone—systemic scleroderma	0.000851	0.000851	CcSEcCtD
Doxylamine—Confusional state—Methotrexate—systemic scleroderma	0.000838	0.000838	CcSEcCtD
Doxylamine—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000831	0.000831	CcSEcCtD
Doxylamine—Feeling abnormal—Prednisone—systemic scleroderma	0.00082	0.00082	CcSEcCtD
Doxylamine—Nervous system disorder—Methotrexate—systemic scleroderma	0.000815	0.000815	CcSEcCtD
Doxylamine—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000814	0.000814	CcSEcCtD
Doxylamine—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000804	0.000804	CcSEcCtD
Doxylamine—Anorexia—Methotrexate—systemic scleroderma	0.000792	0.000792	CcSEcCtD
Doxylamine—Urticaria—Prednisone—systemic scleroderma	0.00079	0.00079	CcSEcCtD
Doxylamine—Hypotension—Methotrexate—systemic scleroderma	0.000777	0.000777	CcSEcCtD
Doxylamine—Insomnia—Methotrexate—systemic scleroderma	0.000752	0.000752	CcSEcCtD
Doxylamine—Dyspnoea—Methotrexate—systemic scleroderma	0.000741	0.000741	CcSEcCtD
Doxylamine—Somnolence—Methotrexate—systemic scleroderma	0.000739	0.000739	CcSEcCtD
Doxylamine—Hypersensitivity—Prednisone—systemic scleroderma	0.000733	0.000733	CcSEcCtD
Doxylamine—Decreased appetite—Methotrexate—systemic scleroderma	0.000723	0.000723	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000718	0.000718	CcSEcCtD
Doxylamine—Fatigue—Methotrexate—systemic scleroderma	0.000717	0.000717	CcSEcCtD
Doxylamine—Asthenia—Prednisone—systemic scleroderma	0.000714	0.000714	CcSEcCtD
Doxylamine—Pruritus—Prednisone—systemic scleroderma	0.000704	0.000704	CcSEcCtD
Doxylamine—Feeling abnormal—Methotrexate—systemic scleroderma	0.000685	0.000685	CcSEcCtD
Doxylamine—Diarrhoea—Prednisone—systemic scleroderma	0.000681	0.000681	CcSEcCtD
Doxylamine—Urticaria—Methotrexate—systemic scleroderma	0.00066	0.00066	CcSEcCtD
Doxylamine—Dizziness—Prednisone—systemic scleroderma	0.000658	0.000658	CcSEcCtD
Doxylamine—Vomiting—Prednisone—systemic scleroderma	0.000632	0.000632	CcSEcCtD
Doxylamine—Rash—Prednisone—systemic scleroderma	0.000627	0.000627	CcSEcCtD
Doxylamine—Dermatitis—Prednisone—systemic scleroderma	0.000627	0.000627	CcSEcCtD
Doxylamine—Hypersensitivity—Methotrexate—systemic scleroderma	0.000613	0.000613	CcSEcCtD
Doxylamine—Asthenia—Methotrexate—systemic scleroderma	0.000596	0.000596	CcSEcCtD
Doxylamine—Nausea—Prednisone—systemic scleroderma	0.000591	0.000591	CcSEcCtD
Doxylamine—Pruritus—Methotrexate—systemic scleroderma	0.000588	0.000588	CcSEcCtD
Doxylamine—Diarrhoea—Methotrexate—systemic scleroderma	0.000569	0.000569	CcSEcCtD
Doxylamine—Dizziness—Methotrexate—systemic scleroderma	0.00055	0.00055	CcSEcCtD
Doxylamine—Vomiting—Methotrexate—systemic scleroderma	0.000529	0.000529	CcSEcCtD
Doxylamine—Rash—Methotrexate—systemic scleroderma	0.000524	0.000524	CcSEcCtD
Doxylamine—Dermatitis—Methotrexate—systemic scleroderma	0.000524	0.000524	CcSEcCtD
Doxylamine—Nausea—Methotrexate—systemic scleroderma	0.000494	0.000494	CcSEcCtD
